But this is unlikely to happen anytime soon, as there is currently no patent on DCA, and thus no incentive for private industry to research its potential benefits as a cancer treatment -- it's all about the money, after all, not public health. And governments are likely to ignore DCA as well, even though the medical research funds they disburse are intended for this very type of research, which is otherwise overlooked by the private sector in favor of more profitable undertakings.
But that has not stopped Dr. Michelakis from conducting his own research on animals, which thus far has shown some promising outcomes in targeting cancer cells and tumors. A recent report aired by CTV News in Canada explains how DCA, a drug that has actually been around for quite a while, is finding new vigor as an effective cancer treatment. What has long been used as a treatment merely for certain rare medical conditions could also be a, dare we say it, cure for cancer.
Based on initial trials, mice intentionally bred with certain human cancers responded positively to DCA when it was added to their drinking water. Brain, breast and lung tumors, it turns out, shrunk by an astounding 70 percent after just three weeks of treatment with DCA. And according to Dr. Michelakis, the drug compound did not cause any harmful side effects, leaving fully intact healthy cells and other tissues that are otherwise damaged by conventional chemotherapy or radiation treatments.
Not only this, but DCA also appears to help reanimate the energy-producing mechanisms found in healthy cells, which are known as mitochondria, giving them new life. Once activated and brought up to speed, these mitochondria elicit new abilities to trigger cancer apoptosis, or cancer cells essentially committing suicide on their own.
"These kinds of results, in my mind, are as good as it gets," stated Dr. Michelakis to CTV News about his findings. "We hope that we can attract the interest of universities here in Canada and in the United States."
Cheap, effective and patent-free means Big Pharma isn't interested
"This is exactly what we want is a drug that has activity, and that also has minimal side effects for patients," added Dr. Dario Altieri from the University of Massachusetts about the promising benefits of DCA.
You can view the full CTV News segment on DCA at LiveLeak.com:
Dr. Michelakis was also recently interviewed by television personality Glenn Beck:
You can also learn more about Dr. Michelakis' work by visiting Canadians for Health Research: